NASDAQ:AVIR Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis $3.47 -0.17 (-4.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.48 +0.00 (+0.14%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Atea Pharmaceuticals Stock (NASDAQ:AVIR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atea Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.46▼$3.6950-Day Range$2.90▼$3.9052-Week Range$2.45▼$4.14Volume313,746 shsAverage Volume376,402 shsMarket Capitalization$296.96 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingModerate Buy Company Overview Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Read More Atea Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreAVIR MarketRank™: Atea Pharmaceuticals scored higher than 34% of companies evaluated by MarketBeat, and ranked 745th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAtea Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAtea Pharmaceuticals has received no research coverage in the past 90 days.Read more about Atea Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atea Pharmaceuticals is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atea Pharmaceuticals is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtea Pharmaceuticals has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Atea Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.26% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Atea Pharmaceuticals has recently increased by 13.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtea Pharmaceuticals does not currently pay a dividend.Dividend GrowthAtea Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.26% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Atea Pharmaceuticals has recently increased by 13.91%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Atea Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for AVIR on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders18.10% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atea Pharmaceuticals' insider trading history. Receive AVIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVIR Stock News HeadlinesAtea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025July 31 at 7:00 AM | globenewswire.comAtea Pharmaceuticals Insiders Placed Bullish Bets Worth US$5.40mJuly 24, 2025 | finance.yahoo.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 2 at 2:00 AM | Brownstone Research (Ad)AVIR Atea Pharmaceuticals, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comAtea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North AmericaJune 24, 2025 | globenewswire.comHere's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn SituationJune 17, 2025 | finance.yahoo.comAtea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comAtea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025May 7, 2025 | globenewswire.comSee More Headlines AVIR Stock Analysis - Frequently Asked Questions How have AVIR shares performed this year? Atea Pharmaceuticals' stock was trading at $3.35 on January 1st, 2025. Since then, AVIR stock has increased by 3.6% and is now trading at $3.47. How were Atea Pharmaceuticals' earnings last quarter? Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) posted its earnings results on Monday, May, 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.16. When did Atea Pharmaceuticals IPO? Atea Pharmaceuticals (AVIR) raised $253 million in an IPO on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO. Who are Atea Pharmaceuticals' major shareholders? Atea Pharmaceuticals' top institutional shareholders include Johnson Investment Counsel Inc. (0.02%). Insiders that own company stock include Jean-Pierre Sommadossi, Andrea Corcoran, Franklin M Berger, Bruce Polsky and Wayne Foster. View institutional ownership trends. How do I buy shares of Atea Pharmaceuticals? Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atea Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), PayPal (PYPL) and Broadcom (AVGO). Company Calendar Last Earnings5/12/2025Today8/02/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVIR CIK1593899 Webwww.ateapharma.com Phone857-284-8891FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for Atea Pharmaceuticals$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+72.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$168.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.26% Return on Assets-29.27% Debt Debt-to-Equity RatioN/A Current Ratio19.94 Quick Ratio19.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.20 per share Price / Book0.67Miscellaneous Outstanding Shares85,580,000Free Float70,089,000Market Cap$296.96 million OptionableOptionable Beta0.25 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AVIR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.